10-Q: Cognition Therapeutics Reports Second Quarter 2024 Results, Cites Progress in Alzheimer's and Dementia Trials

Cognition Therapeutics reported its second quarter 2024 financial results, highlighting ongoing clinical trial progress and a net loss of $16.2 million for the six-month period.

Summary

• Cognition Therapeutics, a biopharmaceutical company, is focused on developing treatments for age-related degenerative diseases of the central nervous system and retina.
• The company's lead product candidate, CT1812, targets the sigma-2 receptor to address dysregulated pathways associated with neurodegenerative diseases.
• The company reported a net loss of $16.2 million for the six months ended June 30, 2024, compared to a net loss of $10.9 million for the same period in 2023.
• Research and development expenses increased to $22.1 million for the first six months of 2024, up from $13.9 million in the same period of 2023, primarily due to increased clinical trial activities.
• The company's cash and cash equivalents were $28.5 million as of June 30, 2024, compared to $29.9 million at the end of 2023.
• The company believes its current cash and cash equivalents are not sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Cognition Therapeutics is relying on grants, equity offerings, and potential collaborations to fund its operations.
• The company completed a follow-on public offering in March 2024, raising net proceeds of approximately $11.9 million.
• The company has an at-the-market (ATM) offering agreement with $34.3 million remaining available and an equity line financing agreement with Lincoln Park Capital Fund, LLC with $34.8 million available to draw.
• The company reported results from its Phase 2 SHINE trial, which showed a consistent trend in cognitive improvement in participants treated with CT1812 compared to placebo across all cognitive measures.
• Topline results from the Phase 2 SHIMMER trial are expected by year-end 2024.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there is positive data from the SHINE trial, the company's financial position and going concern warning are significant negatives. The need for additional funding and the lack of statistical significance on a key secondary endpoint in the SHINE trial temper the positive aspects.

Positives

• The Phase 2 SHINE trial showed a consistent trend in cognitive improvement in participants treated with CT1812 compared to placebo across all cognitive measures.
• The SHINE trial achieved its primary objective and demonstrated a favorable safety and tolerability profile.
• The company has secured significant grant funding from the National Institute of Aging (NIA) to support its clinical trials.
• The company has access to additional capital through an ATM offering and an equity line financing agreement.

Negatives

• The company reported a net loss of $16.2 million for the six months ended June 30, 2024.
• The company's cash and cash equivalents are not sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The company has incurred recurring losses since inception and expects to continue to incur losses for the foreseeable future.
• The SHINE trial did not achieve statistical significance on the first of the ordered secondary efficacy endpoints in the pooled 100mg and 300mg dose group compared to placebo.
• Nine participants in the SHINE trial experienced treatment-emergent liver enzyme test (LFT) increases at the 300mg dose.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company may not be able to obtain additional funding or enter into collaborations on acceptable terms.
• The company's product development programs could be delayed, reduced, or abandoned if funding is not secured.
• The company is subject to the risks typically related to the development of new products, and may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors.
• The company relies on third parties for the manufacture of CT1812, which could lead to supply chain issues.
• The company's clinical trials may be impacted by interruptions or delays at clinical trial sites or operations of the FDA and comparable foreign regulatory authorities.
• The company's ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets.

Future Outlook

The company expects to continue to incur significant and increasing expenses and net losses for the foreseeable future as it advances its product candidates through clinical development and seeks regulatory approval. The company anticipates needing to raise additional funding to support its operations and is exploring various financing options, including public or private equity offerings, debt financings, and potential collaborations.

Management Comments

• Management believes that its cash and cash equivalents as of June 30, 2024 is not sufficient to fund operations for the period through one year after the date of this filing and therefore substantial doubt exists about the company's ability to continue as a going concern.
• Management has concluded that, based on the current operating plan, there is substantial doubt as to whether the company can continue as a going concern for the twelve months following the issuance of this Quarterly Report.

Industry Context

Cognition Therapeutics is operating in the competitive biopharmaceutical industry focused on developing treatments for neurodegenerative diseases. The company's approach of targeting the sigma-2 receptor is distinct from other approaches in clinical development for these diseases. The company's results are being closely watched by investors and competitors in the Alzheimer's and dementia space.

Comparison to Industry Standards

• The company's cash burn rate is typical for a clinical-stage biopharmaceutical company, but the need for additional funding is a common challenge in the industry.
• The company's Phase 2 SHINE trial results, while showing a trend in cognitive improvement, did not achieve statistical significance on the first of the ordered secondary efficacy endpoints, which is a common hurdle in clinical trials.
• The company's reliance on grant funding is a common strategy for early-stage biotech companies, but it also introduces uncertainty regarding future funding.
• The company's approach of targeting the sigma-2 receptor is novel and differentiates it from competitors focusing on other mechanisms of action, such as amyloid beta clearance.
• Companies like Biogen, Eli Lilly, and Eisai are major players in the Alzheimer's space, and Cognition Therapeutics is competing with them for market share and investment.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and the potential for loss of investment if the company is unable to secure additional funding.
• Employees may be impacted by potential cost-cutting measures or layoffs if the company's financial situation worsens.
• Patients with neurodegenerative diseases may benefit from the development of CT1812, but the company's financial challenges could delay or halt the development process.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company will continue to advance its clinical trials for CT1812.
• The company expects to report topline results from its SHIMMER trial by year-end 2024.
• The company will seek additional funding through various means.
• The company will continue to pursue non-dilutive research contributions, or grants, including additional NIA grant funding.

Key Dates

Keywords

Cognition Therapeutics, CT1812, Alzheimer's disease, dementia with Lewy bodies, clinical trials, biopharmaceutical, neurodegenerative diseases, sigma-2 receptor, financial results, going concern